Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Tumor
Oral Cancer
Oropharynx Cancer, Stage III
Cancer
Cancer of Head and Neck
Tumor Metastasis
Cancer, Advanced
Cancer, Metastatic
Tumor Recurrence

Interventions: Drug: Pembrolizumab
Radiation: Radiation therapy
Drug: Cisplatin

First Posted Date: 2017-12-26

Last Posted Date: 2024-08-06

Lead Sponsor: Loren Mell, MD

Target Recruit Count: 114

Registration Number: NCT03383094

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 4 locations

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Biological: Nivolumab

First Posted Date: 2017-12-26

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT03382561

Locations: 🇺🇸
Illinois CancerCare-Macomb, Macomb, Illinois, United States
🇺🇸
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 773 locations

A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy

Phase 2

Completed

Conditions: Locally Advanced Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel
Radiation: concomitant radiotherapy
Drug: Cisplatin

First Posted Date: 2017-12-13

Last Posted Date: 2017-12-13

Lead Sponsor: Centre Antoine Lacassagne

Target Recruit Count: 44

Registration Number: NCT03371550

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2

Terminated

Conditions: Cervical Cancer

Interventions: Drug: Pembrolizumab
Drug: Paclitaxel
Drug: Cisplatin
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2017-12-11

Last Posted Date: 2024-06-18

Lead Sponsor: University of Miami

Target Recruit Count: 17

Registration Number: NCT03367871

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Carcinoma
Stage I Non-Small Cell Lung Cancer
Stage IIB Non-Small Cell Lung Carcinoma
Stage IA Non-Small Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Gemcitabine Hydrochloride
Drug: Cisplatin
Drug: Pemetrexed Disodium

First Posted Date: 2017-12-08

Last Posted Date: 2023-04-03

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT03366766

Locations: 🇺🇸
Abington Hospital - Jefferson Health, Abington, Pennsylvania, United States
🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum

Not Applicable

Recruiting

Conditions: Osteosarcoma of Pelvis

Interventions: Drug: Doxorubicin
Drug: Cisplatin
Drug: Methotrexate
Drug: Ifosfamide
Procedure: definitive surgery
Other: pre surgical chemotherapy

First Posted Date: 2017-12-04

Last Posted Date: 2018-08-28

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 100

Registration Number: NCT03360760

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Pembrolizumab
Drug: Cetuximab
Drug: Epacadostat
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-Fluorouracil

First Posted Date: 2017-11-30

Last Posted Date: 2024-06-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 89

Registration Number: NCT03358472

Locations: 🇺🇸
U of Kansas Cancer Center, Westwood, Kansas, United States
🇦🇺
Royal Brisbane & Women s Hospital, Herston, Queensland, Australia
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 70 locations

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: Nivolumab
Drug: Placebo
Drug: Epacadostat
Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2017-11-21

Last Posted Date: 2019-06-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 2

Registration Number: NCT03348904

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Phase 3

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Cetuximab
Biological: Nivolumab
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2017-11-21

Last Posted Date: 2021-08-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 74

Registration Number: NCT03349710

Locations: 🇺🇸
Cancer Treatment Centers of Phoneix, Goodyear, Arizona, United States
🇺🇸
Pinnacle Research Group, Llc, Anniston, Alabama, United States
🇺🇸
UCLA Health, Los Angeles, California, United States

and more 19 locations

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Phase 1

Terminated

Conditions: Cervical Carcinoma
Endometrioid Adenocarcinoma
Malignant Female Reproductive System Neoplasm
Recurrent Cervical Carcinoma
Stage I Uterine Corpus Cancer AJCC v7
Stage I Vaginal Cancer AJCC v6 and v7
Stage IA Uterine Corpus Cancer AJCC v7
Stage IB Cervical Cancer AJCC v6 and v7
Stage IB Uterine Corpus Cancer AJCC v7
Stage IB2 Cervical Cancer AJCC v6 and v7

Interventions: Drug: Adavosertib
Drug: Cisplatin
Radiation: External Beam Radiation Therapy

First Posted Date: 2017-11-17

Last Posted Date: 2024-02-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03345784

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy